PUBLISHER: Inkwood Research | PRODUCT CODE: 1069199
PUBLISHER: Inkwood Research | PRODUCT CODE: 1069199
Europe Drug Discovery Market Forecast 2022-2030
KEY FINDINGS
The Europe drug discovery market is anticipated to project a CAGR of 6.90% during the forecast period, 2022-2030. The rising collaborations for drug discovery and development, advanced technologies, and increased R&D expenses influence market growth in the region.
MARKET INSIGHTS
Italy, Russia, France, Germany, the United Kingdom, Spain, Scandinavia, and Rest of Europe are analyzed for the Europe drug discovery market growth evaluation. In Germany, the pharmaceutical industry is witnessing increasing investments. Also, in 2019 the research-based pharmaceutical companies financed 499 clinical trials. In the same year, companies in pharma R&D were developing 640 biologics in clinical development, out of which 82% of Phase III assets were new biological entities. Biologicals development majorly prioritizes infectious diseases, immunology, and oncology.
In Italy, AIFA (Italian Medicines Agency) is the national authority that overlooks drugs regulations. It operates transparently and autonomously, adhering to the cost-effectiveness aspect, under the direction and vigilance of the Ministry of Health and the Ministry of Economy. Spain is a conducive country for developing clinical trials for new drugs. Its research and development model for new medicines is collaborative and gaining international prospects. Such aspects bring about research investment by pharmaceutical companies in the country.
Furthermore, high-end technological advancements, a skilled workforce, and the presence of prominent pharmaceutical players render Europe one of the leading markets for drug discovery. The presence of the European Medical Agency (EMA) and the European Commission laws further contribute to the region's market prospects.
COMPETITIVE INSIGHTS
Some of the major companies operating in the market include: Novartis AG, Johnson & Johnson, Merck & Co Inc, Pfizer Inc, etc.
Our report offerings include:
- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
- 1.1. STUDY OBJECTIVES
- 1.2. SCOPE OF STUDY
- 1.3. METHODOLOGY
- 1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
- 2.1. MARKET SIZE & ESTIMATES
- 2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
- 3.1. KEY DRIVERS
- 3.1.1. GROWING R&D FOR TACKLING SEVERAL DISEASES
- 3.1.2. TECHNOLOGICAL ADVANCEMENTS
- 3.2. KEY RESTRAINTS
- 3.2.1. EXTENSIVE TIME-CONSUMING PROCESS
- 3.2.2. HIGHLY REGULATED MARKET
- 3.2.3. PROJECT FEASIBILITY AND SUCCESS RATE
4. KEY ANALYTICS
- 4.1. IMPACT OF COVID-19 ON DRUG DISCOVERY INDUSTRY
- 4.2. KEY MARKET TRENDS
- 4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
- 4.4. OPPORTUNITY MATRIX
- 4.5. DRUG DISCOVERY AND DEVELOPMENT PROCESS
- 4.5.1. DRUG DISCOVERY AND DEVELOPMENT
- 4.5.2. PRECLINICAL RESEARCH
- 4.5.3. CLINICAL RESEARCH
- 4.5.4. REGULATORY AUTHORITY REVIEW
- 4.5.5. POST MARKET SAFETY MONITORING
- 4.6. REGULATORY FRAMEWORK
5. MARKET BY DRUG TYPE
- 5.1. SMALL MOLECULE DRUG
- 5.2. BIOLOGIC DRUG
6. MARKET BY SERVICE
- 6.1. CHEMICAL SERVICES
- 6.2. DRUG METABOLISM AND PHARMACOKINETICS SERVICES
- 6.3. BIOLOGICAL SERVICES
- 6.4. OTHER PHARMACEUTICAL SERVICES
7. MARKET BY END-USER
- 7.1. PHARMACEUTICAL COMPANIES
- 7.2. CONTRACT RESEARCH ORGANIZATIONS
- 7.3. RESEARCH INSTITUTES
- 7.4. OTHER END-USERS
8. MARKET BY TECHNOLOGY
- 8.1. HIGH THROUGHPUT SCREENING
- 8.2. SPECTROSCOPY
- 8.3. COMBINATORIAL CHEMISTRY
- 8.4. BIOCHIPS
- 8.5. PHARMACOGENOMICS AND PHARMACOGENETICS
- 8.6. BIOINFORMATICS
- 8.7. METABOLOMICS
- 8.8. NANOTECHNOLOGY
- 8.9. OTHER TECHNOLOGIES
9. GEOGRAPHICAL ANALYSIS
- 9.1. EUROPE
- 9.1.1. MARKET SIZE & ESTIMATES
- 9.1.2. KEY GROWTH ENABLERS
- 9.1.3. KEY CHALLENGES
- 9.1.4. KEY PLAYERS
- 9.1.5. COUNTRY ANALYSIS
- 9.1.5.1. UNITED KINGDOM
- 9.1.5.2. GERMANY
- 9.1.5.3. FRANCE
- 9.1.5.4. ITALY
- 9.1.5.5. RUSSIA
- 9.1.5.6. SPAIN
- 9.1.5.7. SCANDINAVIA
- 9.1.5.8. REST OF EUROPE
10. COMPETITIVE LANDSCAPE
- 10.1. KEY STRATEGIC DEVELOPMENTS
- 10.1.1. MERGERS & ACQUISITIONS
- 10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 10.1.3. PARTNERSHIPS & AGREEMENTS
- 10.1.4. BUSINESS EXPANSIONS & DIVESTITURES
- 10.2. COMPANY PROFILES
- 10.2.1. AGILENT TECHNOLOGIES INC
- 10.2.2. ASTRAZENECA PLC
- 10.2.3. BAYER AG
- 10.2.4. CHARLES RIVER LABORATORIES INTERNATIONAL INC
- 10.2.5. ELI LILLY AND COMPANY
- 10.2.6. EVOTEC SE
- 10.2.7. GLAXOSMITHKLINE PLC
- 10.2.8. ICON PLC
- 10.2.9. IQVIA HOLDINGS INC
- 10.2.10. JOHNSON & JOHNSON
- 10.2.11. MERCK & CO INC
- 10.2.12. NOVARTIS AG
- 10.2.13. PFIZER INC
- 10.2.14. ROCHE AG
LIST OF TABLES
- TABLE 1: MARKET SNAPSHOT - EUROPE DRUG DISCOVERY
- TABLE 2: REGULATORY FRAMEWORK
- TABLE 3: EUROPE DRUG DISCOVERY MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 4: EUROPE DRUG DISCOVERY MARKET, BY DRUG TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 5: EUROPE DRUG DISCOVERY MARKET, BY SERVICE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 6: EUROPE DRUG DISCOVERY MARKET, BY SERVICE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 7: EUROPE DRUG DISCOVERY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 8: EUROPE DRUG DISCOVERY MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 9: EUROPE DRUG DISCOVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 10: EUROPE DRUG DISCOVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 11: EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
- TABLE 12: EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
- TABLE 13: LEADING PLAYERS OPERATING IN EUROPE DRUG DISCOVERY MARKET
- TABLE 14: LIST OF MERGERS & ACQUISITIONS
- TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
- TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS
- TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES
LIST OF FIGURES
- FIGURE 1: KEY MARKET TRENDS
- FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
- FIGURE 3: OPPORTUNITY MATRIX
- FIGURE 4: DRUG DISCOVERY AND DEVELOPMENT PROCESS
- FIGURE 5: EUROPE DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2021
- FIGURE 6: EUROPE DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2022-2030 (IN $ MILLION)
- FIGURE 7: EUROPE DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2022-2030 (IN $ MILLION)
- FIGURE 8: EUROPE DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY SERVICE, IN 2021
- FIGURE 9: EUROPE DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2022-2030 (IN $ MILLION)
- FIGURE 10: EUROPE DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS SERVICES, 2022-2030 (IN $ MILLION)
- FIGURE 11: EUROPE DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2022-2030 (IN $ MILLION)
- FIGURE 12: EUROPE DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2022-2030 (IN $ MILLION)
- FIGURE 13: EUROPE DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
- FIGURE 14: EUROPE DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2022-2030 (IN $ MILLION)
- FIGURE 15: EUROPE DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS, 2022-2030 (IN $ MILLION)
- FIGURE 16: EUROPE DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)
- FIGURE 17: EUROPE DRUG DISCOVERY MARKET, BY OTHER END-USERS, 2022-2030 (IN $ MILLION)
- FIGURE 18: EUROPE DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021
- FIGURE 19: EUROPE DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2022-2030 (IN $ MILLION)
- FIGURE 20: EUROPE DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2022-2030 (IN $ MILLION)
- FIGURE 21: EUROPE DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2022-2030 (IN $ MILLION)
- FIGURE 22: EUROPE DRUG DISCOVERY MARKET, BY BIOCHIPS, 2022-2030 (IN $ MILLION)
- FIGURE 23: EUROPE DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2022-2030 (IN $ MILLION)
- FIGURE 24: EUROPE DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2022-2030 (IN $ MILLION)
- FIGURE 25: EUROPE DRUG DISCOVERY MARKET, BY METABOLOMICS, 2022-2030 (IN $ MILLION)
- FIGURE 26: EUROPE DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2022-2030 (IN $ MILLION)
- FIGURE 27: EUROPE DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2022-2030 (IN $ MILLION)
- FIGURE 28: EUROPE DRUG DISCOVERY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
- FIGURE 29: UNITED KINGDOM DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 30: GERMANY DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 31: FRANCE DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 32: ITALY DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 33: RUSSIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 34: SPAIN DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 35: SCANDINAVIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
- FIGURE 36: REST OF EUROPE DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
